Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40272-015-0130-8 http://scihub22266oqcxt.onion/10.1007/s40272-015-0130-8 C5870137!5870137!25911294     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Paediatr+Drugs 2015 ; 17 (4): 273-81 Nephropedia Template TP {{tp|p=25911294|t=2015. Central Precocious Puberty: Update on Diagnosis and Treatment |pdf=|usr=}}{{25911294}} gab.com Text Central Precocious Puberty: Update on Diagnosis and Treatment JO: Paediatr Drugs http://www.kidney.de/pget.php?&tw=1&pmid=25911294 #FOAvip Central precocious puberty (CPP) is characterized by the same biochemical and physical features as normally timed puberty but occurs at an abnormally early age. Most cases of CPP are seen in girls, in whom it is usually idiopathic. In contrast, ?50 % of boys with CPP have an identifiable cause. The diagnosis of CPP relies on clinical, biochemical, and radiographic features. Untreated, CPP has the potential to result in early epiphyseal fusion and a significant compromise in adult height. Thus, the main goal of therapy is preservation of height potential. The gold-standard treatment for CPP is go-nadotropin-releasing hormone (GnRH) analogs (GnRHa). Numerous preparations with a range of delivery systems and durations of action are commercially available. While the outcomes of patients treated for CPP have generally been favorable, more research about the psychological aspects, optimal monitoring, and long-term effects of all forms of GnRHa treatment is needed. Several potential therapeutic alternatives to GnRHa exist and await additional investigation. Twit Text FOAVip Central Precocious Puberty: Update on Diagnosis and Treatment ????Paediatr Drugs http://www.kidney.de/pget.php?&tw=1&pmid=25911294 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25911294 #FOAvip English Wikipedia <ref>{{Cite pmid|25911294}}</ref> Central Precocious Puberty: Update on Diagnosis and Treatment #MMPMID25911294 Chen M; Eugster EA Paediatr Drugs 2015[Aug]; 17 (4): 273-81 PMID25911294show ga Central precocious puberty (CPP) is characterized by the same biochemical and physical features as normally timed puberty but occurs at an abnormally early age. Most cases of CPP are seen in girls, in whom it is usually idiopathic. In contrast, ?50 % of boys with CPP have an identifiable cause. The diagnosis of CPP relies on clinical, biochemical, and radiographic features. Untreated, CPP has the potential to result in early epiphyseal fusion and a significant compromise in adult height. Thus, the main goal of therapy is preservation of height potential. The gold-standard treatment for CPP is go-nadotropin-releasing hormone (GnRH) analogs (GnRHa). Numerous preparations with a range of delivery systems and durations of action are commercially available. While the outcomes of patients treated for CPP have generally been favorable, more research about the psychological aspects, optimal monitoring, and long-term effects of all forms of GnRHa treatment is needed. Several potential therapeutic alternatives to GnRHa exist and await additional investigation. äCentral Precocious Puberty: Update on Diagnosis and Treatment (epmc).pdf DeepDyve Pubget Overpricing